Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINAPPS2 trial of IVIG and rituximab for antibody-associated psychosis
2016-000118-31Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psychosis comparing IVIG + rituximab with Placebo (2 arms). Primary endpoint: Time to start of remission sustained for 6 months. Status: unknown.
02
Drugs
subcuviarituximab
03
Conditions
psychosis
Beyond the preview
Go deeper on 2016-000118-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000118-31.